University College London

Human heart
#Cardiovascular disease #GLP-1 #Heart failure #Obesity #University College London #Weight loss

Semaglutide could also benefit patients with heart failure

A new study indicates that anti-obesity drug semaglutide helps prevent cardiac events among overweight people who have cardiovascular disease, even if they also have heart failure. The results follow a previous finding that weekly injections of semaglutide were linked to a 20% reduction in major adverse cardiac events (MACE) such… Read More

#News #Trending News

Patient on ventilator
#Covid-19 #Covid-19 treatment #Drug repurposing #Francis Crick Institute #Pneumonia #University College London

Repurposed drug treats severe Covid-19 pneumonia

A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe Covid-19 pneumonia in a recent clinical trial. The drug, dornase alfa, could be used to treat other respiratory infections, according to the data from researchers at UCL, UCLH and the Francis Crick… Read More

#News #Trending News

Patient using blood pressure monitor
#Cardiovascular disease #Novo Nordisk #Obesity #University College London #Weight loss

Ozempic could be a gamechanger for cardiovascular disease

Semaglutide (the active ingredient in Wegovy and Ozempic) can produce clinically meaningful weight loss and delivers significant cardiovascular benefits, according to two studies presented at the European Congress on Obesity (ECO). The studies are based on the Semaglutide and Cardiovascular Outcomes (SELECT) trial, the largest and… Read More

#News #Trending News

Kidneys
#Chronic kidney disease (CKD) #Kidney disease #Rare disease #UK Kidney Association #University College London

Focus on rare disease treatments to beat kidney failure, says study

Focusing on rare conditions could significantly reduce the burden of kidney disease, according to a new study led by University College London (UCL) and the UK Kidney Association. The study, published in The Lancet to mark World Kidney Day on 14 March, draws on the largest… Read More

#News

#Clinical trial design #Dementia #Funding #Neurodegenerative disorders #University College London

UK dementia research gets £49.9 million funding boost

Head of clinical trials at the University College London (UCL) Dementia Research Centre, Dr Cath Mummery, has been announced as the Director of a new network of dementia trial sites across the country. The UK government has authorised £49.9 ($63.4) million of new funding to improve… Read More

#Editor's Choice #News

Covid-19
#Covid variants #Covid-19 #Immunity #Omicron #University College London #University of Glasgow

Revealed: How Covid-19 variants stay ahead of immune defences

Recent SARS-CoV-2 variants such as BA.4 and BA.5 developed abilities missing from the first Omicron variants that allowed them to overcome humans’ innate immunity, according to research from University College London (UCL). The study examined viral evolution in eight Omicron variants to better understand how the… Read More

#News #Trending News

mRNA
#King's College London #Liver disease #Moderna #Mouse models #mRNA #Rare disease #University College London

Study reveals therapeutic potential of mRNA in rare diseases

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. The team, led by University College London (UCL), King’s College London and Moderna scientists, found that mRNA could be… Read More

#Editor's Choice #News

MRI of the brain
#epilepsy #Gene therapy #Mouse models #Preclinical investigations #University College London

Gene therapy could reduce seizures in childhood epilepsy

University College London (UCL) researchers have developed a new gene therapy to cure focal cortical dysplasia, which a new study shows can significantly reduce seizures in mice. Focal cortical dysplasia is caused by areas of the brain that have developed abnormally and is among the most… Read More

#Editor's Choice #News

Blood cancer
#Acute Myeloid Leukaemia #Biologics #Blood cancer #CAR-T #University College London #ViroCell Biologics

UCL accelerates research of relapse in childhood blood cancer 

The University College London (UCL) has entered into a partnership with ViroCell Biologics to advance Professor Persis Amrolia’s innovative chimeric antigen receptor (CAR) T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia (ALL).   Dr Amrolia is Professor of Transplantation Immunology at the UCL Great Ormond Street Institute of… Read More

#Cancer Research #News

Colon cancer
#Bowel cancer #Cancer research #Chemotherapy-resistance #Oncology #University College London #Yale University

New discovery could make bowel cancer treatment more effective

Chemotherapy becomes less effective because healthy cells push cancer cells to grow more slowly, according to the findings of two studies from University College London (UCL) and Yale University. Bowel cancer kills over 900,000 people a year and is the second highest cause of cancer mortality… Read More

#Cancer Research #Editor's Choice #News

MRI of the brain
#Alzheimer's #AstronauTx #Financing #Neurodegenerative disorders #University College London

UCL spinout raises £48m funding for new approach to Alzheimer’s

University College London (UCL) spinout AstronauTx has closed a £48m ($61m) Series A financing to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. The company was launched in 2019, initially to build on research from the Alzheimer's Research UK UCL Drug Discovery Institute (UCL DDI). Protoplasmic astrocytes play… Read More

#Business & Investment #News

Click chemistry
#Cancer research #Click chemistry #Immunotherapy #Oncology #Stanford University #University College London

Novel anti-cancer therapy created using click chemistry

A potent anti-cancer therapy has been created using Nobel prize-winning “click chemistry”, in a new study by University College London (UCL) and Stanford University researchers. The study, published in Nature Chemistry, opens up new possibilities for how cancer immunotherapies might be built in… Read More

#Cancer Research #News #Trending News

New Domainex facility
#Contract Research Organisations (CROs) #Domainex #UK #University College London

Domainex expands research operations with new facility

Research services provider Domainex has secured a new, fully fitted, three-storey building in Unity Campus in Cambridgeshire, UK. Domainex first moved to Unity Campus in January 2022, taking 7,000 sq ft of laboratory space at Iconix 2 to provide a dedicated facility for its biology department… Read More

#News

Lung cancer
#Cancer research #Immunotherapy #Lung cancer #Oncology #Roche #University College London

Immunotherapy improves lung cancer long-term survival

A global study, led by University College London (UCL) and University College London Hospitals (UCLH) and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer (NSCLC) patients, when compared to single-agent chemotherapy. For… Read More

#Cancer Research #News

Molecular glues
#AstraZeneca #Francis Crick Institute #Molecular research #Oncology #University College London

Molecular glues could tackle ‘undruggable’ disease targets

UK researchers at the Francis Crick Institute, Imperial College London and AstraZeneca will advance the discovery of new ‘molecular glues’ to treat a range of different diseases, thanks to a £11.2 million combined investment. The investment includes a Prosperity Partnership grant from the Engineering and Physical… Read More

#Editor's Choice #News